BRPI0809309A2 - Composições farmacêuticas sinérgicas que compreendem a combinação de um inibidor da enzima 5 alfa-redutase e um antagonista dos receptores 1 alfa-adrenérgicos. - Google Patents

Composições farmacêuticas sinérgicas que compreendem a combinação de um inibidor da enzima 5 alfa-redutase e um antagonista dos receptores 1 alfa-adrenérgicos.

Info

Publication number
BRPI0809309A2
BRPI0809309A2 BRPI0809309-1A2A BRPI0809309A BRPI0809309A2 BR PI0809309 A2 BRPI0809309 A2 BR PI0809309A2 BR PI0809309 A BRPI0809309 A BR PI0809309A BR PI0809309 A2 BRPI0809309 A2 BR PI0809309A2
Authority
BR
Brazil
Prior art keywords
alpha
adrenger
angonist
receptors
enzyme
Prior art date
Application number
BRPI0809309-1A2A
Other languages
English (en)
Inventor
Maria Elena Garcia Armenta
Josefina Santos Murillo
Victor Guillermo Alvarez Ochoa
Original Assignee
World Trade Imp Export Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39808488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0809309(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by World Trade Imp Export Wtie Ag filed Critical World Trade Imp Export Wtie Ag
Publication of BRPI0809309A2 publication Critical patent/BRPI0809309A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0809309-1A2A 2007-04-02 2008-01-29 Composições farmacêuticas sinérgicas que compreendem a combinação de um inibidor da enzima 5 alfa-redutase e um antagonista dos receptores 1 alfa-adrenérgicos. BRPI0809309A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2007003949A MX2007003949A (es) 2007-04-02 2007-04-02 Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima (-reductasa y un antagonista de los receptores 1 (-adrenergicos.
PCT/MX2008/000012 WO2008120967A1 (es) 2007-04-02 2008-01-29 COMPOSICIONES FARMACÉUTICAS SINERGICAS QUE COMPRENDEN LA COMBINACIÓN DE UN INHIBIDOR DE LA ENZIMA 5 α-REDUCTASA Y UN ANTAGONISTA DE LOS RECEPTORES 1 α- ADRENERGICOS.

Publications (1)

Publication Number Publication Date
BRPI0809309A2 true BRPI0809309A2 (pt) 2014-10-14

Family

ID=39808488

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809309-1A2A BRPI0809309A2 (pt) 2007-04-02 2008-01-29 Composições farmacêuticas sinérgicas que compreendem a combinação de um inibidor da enzima 5 alfa-redutase e um antagonista dos receptores 1 alfa-adrenérgicos.

Country Status (10)

Country Link
EP (1) EP2156836B1 (pt)
AR (1) AR065918A1 (pt)
BR (1) BRPI0809309A2 (pt)
CL (1) CL2008000964A1 (pt)
CO (1) CO6140029A2 (pt)
EC (2) ECSP099650A (pt)
ES (1) ES2656426T3 (pt)
GT (1) GT200900275A (pt)
MX (1) MX2007003949A (pt)
WO (1) WO2008120967A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162776A1 (pt) * 2011-06-03 2012-12-06 Eurofarma Laboratórios S.A Composição farmacêutica para o tratamento de hiperplasia prostática benigna
DE212018000251U1 (de) * 2017-06-30 2020-05-12 Antev Limited Zusammensetzung zur Behandlung akuter Harnverhaltung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
WO2001021167A1 (en) * 1999-09-22 2001-03-29 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein

Also Published As

Publication number Publication date
CO6140029A2 (es) 2010-03-19
EP2156836A4 (en) 2011-01-26
WO2008120967A1 (es) 2008-10-09
CL2008000964A1 (es) 2009-03-20
EP2156836A1 (en) 2010-02-24
AR065918A1 (es) 2009-07-08
EP2156836B1 (en) 2017-10-18
GT200900275A (es) 2016-01-21
ES2656426T3 (es) 2018-02-27
ECSP099650A (es) 2009-10-30
ECSP099649A (es) 2009-10-30
MX2007003949A (es) 2009-02-25

Similar Documents

Publication Publication Date Title
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
CL2007002916A1 (es) Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
EP2124556A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BRPI0818804A2 (pt) Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
BRPI0811612A2 (pt) Composições farmacêuticas que contêm agonista ppardelta
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
ES2465478T8 (es) Composiciones farmacéuticas que comprenden brivaracetam
SM201000108A (it) Composti e composizioni come inibitori di proteinachinasi.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
MX2008006580A (es) Composicion de cereal que comprende edulcorante de alta potencia
ES2527409T4 (es) Formulaciones de inhibidores de DPP IV
EA200802008A1 (ru) Фармацевтические композиции
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0720211A2 (pt) Derivado de indanona, composição, e, uso de uma composição
DK3103448T3 (da) Farmaceutiske sammensætninger, der omfatter en S1P-modulator
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0908208A2 (pt) Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto.
BRPI0813922A2 (pt) composições de inibição de influenza e métodos.
EP2154966A4 (en) BENZIMIDAZOLE AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
CL2007002021A1 (es) Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BRPI0810399A2 (pt) Composto, composição farmacêutica que o contém e uso do mesmo

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PPTM INTERNATIONAL, S.A.R.L. (LU)

B25A Requested transfer of rights approved

Owner name: TEVA PHARMACEUTICALS HOLDINGS MEXICO S.A. DE C.V.

B25A Requested transfer of rights approved

Owner name: REPRESENTACIONES E INVESTIGACIONES MEDICAS, S.A. DE C.V (MX)

Owner name: REPRESENTACIONES E INVESTIGACIONES MEDICAS, S.A. D

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]